Targeting Microglial C5aR1 with PMX205 Attenuates Neuroinflammation and Improves Neurological Recovery After Intracerebral Hemorrhage
Neurochemical Research · 2026
DOI: 10.1007/s11064-026-04858-9 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neurochemical Research, 2026. Verfasst von Xuan Shi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Brain and Nerve Research Laboratory, The First Affiliated Hospital of Soochow University, Soochow University, Suzhou, 215…. Hauptthemen laut MEDLINE: Microglia, Receptor, Anaphylatoxin C5a, Cerebral Hemorrhage, Neuroinflammatory Diseases. Die Arbeit nennt 46 Literaturangaben. Gefördert von: the National Natural Science Foundation of China, the Science and Education Foundation for Health of Suzhou for Youth, the Basic Research Pilot Project of Suzhou.
Abstract (Originalsprache)
Activation of microglia and inflammatory response play a central role in the pathological process following intracerebral hemorrhage (ICH). In this study, single-nucleus transcriptomic and proteomic profiling was performed to investigate microglial changes after ICH. A significant upregulation of complement receptor C5aR1 was identified, particularly enriched in microglial subsets exhibiting a pro-inflammatory phenotype. The cellular localization and temporal expression dynamics of C5aR1 were validated by immunofluorescence staining, Western blotting, and quantitative PCR, demonstrating its sustained elevation in microglia after ICH. Pharmacological inhibition with the selective C5aR1 antagonist PMX205 markedly reduced the release of inflammatory cytokines, alleviated neuronal damage, and improved neurological function. Proteomic profiling and subsequent validation suggested that CCR5 may be associated with C5aR1-related inflammatory responses after ICH. Collectively, these findings suggest that C5aR1 serves as a regulatory factor in microglia-mediated neuroinflammation following ICH, and that targeting this pathway may offer a promising therapeutic strategy for hemorrhagic stroke.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurosurgery, Brain and Nerve Research Laboratory, The First Affiliated Hospital of Soochow University, Soochow University, Suzhou, 215006, China.
- Institute of Stroke Research, Soochow University, Suzhou, 215006, China.
- Department of Neurosurgery, Brain and Nerve Research Laboratory, The First Affiliated Hospital of Soochow University, Soochow University, Suzhou, 215006, China. qiu_youjia@163.com.
- Institute of Stroke Research, Soochow University, Suzhou, 215006, China. qiu_youjia@163.com.
- Department of Neurosurgery, Brain and Nerve Research Laboratory, The First Affiliated Hospital of Soochow University, Soochow University, Suzhou, 215006, China. lhy1015@suda.edu.cn.
- Institute of Stroke Research, Soochow University, Suzhou, 215006, China. lhy1015@suda.edu.cn.
Förderung
- the National Natural Science Foundation of China
- the Science and Education Foundation for Health of Suzhou for Youth
- the Basic Research Pilot Project of Suzhou
Zitieren
APA
Shi, X., Li, X., Ding, H., Cao, C., Liu, J., Li, S., Qiu, Y., Li, H., & Li, X. (2026). Targeting Microglial C5aR1 with PMX205 Attenuates Neuroinflammation and Improves Neurological Recovery After Intracerebral Hemorrhage. Neurochemical Research. https://doi.org/10.1007/s11064-026-04858-9
Vancouver
Shi X, Li X, Ding H, Cao C, Liu J, Li S, et al. Targeting Microglial C5aR1 with PMX205 Attenuates Neuroinflammation and Improves Neurological Recovery After Intracerebral Hemorrhage. Neurochemical Research. 2026. doi:10.1007/s11064-026-04858-9
BibTeX
@article{Shi2026,
author = {Shi, Xuan and Li, Xueyan and Ding, Haojie and Cao, Chang and Liu, Jiale and Li, Shuangkai and Qiu, Youjia and Li, Haiying and Li, Xiang},
title = {Targeting Microglial C5aR1 with PMX205 Attenuates Neuroinflammation and Improves Neurological Recovery After Intracerebral Hemorrhage},
journal = {Neurochemical Research},
year = {2026},
doi = {10.1007/s11064-026-04858-9}
}
EUVIMED